These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34074778)

  • 41. Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes.
    Hay ZLZ; Knapp JR; Magallon RE; O'Connor BP; Slansky JE
    Cancer Immunol Res; 2023 May; 11(5):570-582. PubMed ID: 36787375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.
    Soong RS; Song L; Trieu J; Lee SY; He L; Tsai YC; Wu TC; Hung CF
    PLoS One; 2014; 9(3):e93162. PubMed ID: 24664420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.
    Schmitt TM; Aggen DH; Stromnes IM; Dossett ML; Richman SA; Kranz DM; Greenberg PD
    Blood; 2013 Jul; 122(3):348-56. PubMed ID: 23673862
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens.
    Palena C; Arlen P; Zeytin H; Greiner JW; Schlom J; Tsang KY
    Cytokine; 2003 Nov; 24(4):128-42. PubMed ID: 14572791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen.
    Speiser DE; Baumgaertner P; Voelter V; Devevre E; Barbey C; Rufer N; Romero P
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3849-54. PubMed ID: 18319339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.
    Simon P; Omokoko TA; Breitkreuz A; Hebich L; Kreiter S; Attig S; Konur A; Britten CM; Paret C; Dhaene K; Türeci Ö; Sahin U
    Cancer Immunol Res; 2014 Dec; 2(12):1230-44. PubMed ID: 25245536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.
    Assudani D; Cho HI; DeVito N; Bradley N; Celis E
    Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.
    Tang Y; Zhang L; Yuan J; Akbulut H; Maynard J; Linton PJ; Deisseroth A
    Blood; 2004 Nov; 104(9):2704-13. PubMed ID: 15238426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
    Kiessling A; Schmitz M; Stevanovic S; Weigle B; Hölig K; Füssel M; Füssel S; Meye A; Wirth MP; Rieber EP
    Int J Cancer; 2002 Dec; 102(4):390-7. PubMed ID: 12402309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.
    Gee MH; Han A; Lofgren SM; Beausang JF; Mendoza JL; Birnbaum ME; Bethune MT; Fischer S; Yang X; Gomez-Eerland R; Bingham DB; Sibener LV; Fernandes RA; Velasco A; Baltimore D; Schumacher TN; Khatri P; Quake SR; Davis MM; Garcia KC
    Cell; 2018 Jan; 172(3):549-563.e16. PubMed ID: 29275860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
    Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in antigen recognition and cytolytic activity of CD8(+) and CD8(-) T cells that express the same antigen-specific receptor.
    Cho BK; Lian KC; Lee P; Brunmark A; McKinley C; Chen J; Kranz DM; Eisen HN
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1723-7. PubMed ID: 11172018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cross-reactive CD8
    Cavalluzzo B; Viuff MC; Tvingsholm SA; Ragone C; Manolio C; Mauriello A; Buonaguro FM; Tornesello ML; Izzo F; Morabito A; Hadrup SR; Tagliamonte M; Buonaguro L
    J Exp Clin Cancer Res; 2024 Mar; 43(1):87. PubMed ID: 38509571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
    Cole DJ; Weil DP; Shamamian P; Rivoltini L; Kawakami Y; Topalian S; Jennings C; Eliyahu S; Rosenberg SA; Nishimura MI
    Cancer Res; 1994 Oct; 54(20):5265-8. PubMed ID: 7522957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands.
    de Visser KE; Cordaro TA; Kessels HW; Tirion FH; Schumacher TN; Kruisbeek AM
    J Immunol; 2001 Oct; 167(7):3818-28. PubMed ID: 11564799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
    Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
    J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.
    Belnoue E; Mayol JF; Carboni S; Di Berardino Besson W; Dupuychaffray E; Nelde A; Stevanovic S; Santiago-Raber ML; Walker PR; Derouazi M
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
    Martínez-Usatorre A; Donda A; Zehn D; Romero P
    J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.